Potassium canrenoate

(Redirected from Potassium canreonate)

Potassium canrenoate (INN, JAN) or canrenoate potassium (USAN) (brand names Venactone, Soldactone), also known as aldadiene kalium,[1] the potassium salt of canrenoic acid, is an aldosterone antagonist of the spirolactone group.[2] Like spironolactone, it is a prodrug, and is metabolized to active canrenone in the body.[3][4]

Potassium canrenoate
Clinical data
Other namesSC-14266
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Intravenous
ATC code
Pharmacokinetic data
MetabolismHepatic
ExcretionRenal and fecal
Identifiers
  • potassium 3-[(8R,9S,10R,13S,14S,17R)-
    17-hydroxy-10,13-dimethyl-3-oxo-2,8,9,
    11,12,14,15,16-octahydro-1H-cyclopenta[a]
    phenanthren-17-yl]propanoate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.016.868 Edit this at Wikidata
Chemical and physical data
FormulaC22H29KO4
Molar mass396.568 g·mol−1
3D model (JSmol)
  • [K+].[O-]C(=O)CC[C@]3(O)CC[C@H]2[C@@H]4/C=C\C1=C\C(=O)CC[C@@]1([C@H]4CC[C@@]23C)C
  • InChI=1S/C22H30O4.K/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25;/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25);/q;+1/p-1/t16-,17+,18+,20+,21+,22-;/m1./s1 checkY
  • Key:JTZQCHFUGHIPDF-RYVBEKKQSA-M checkY
 ☒NcheckY (what is this?)  (verify)

Potassium canrenoate is notable in that it is the only clinically used antimineralocorticoid which is available for parenteral administration (specifically intravenous)[4][5] as opposed to oral administration.[6]

In the UK, it is unlicensed and only used for short term diuresis in oedema or heart failure in neonates or children under specialist initiation and monitoring.

See also

edit

References

edit
  1. ^ Selye H (17 April 2013). Hormones and Resistance: Part 1 and. Springer Science & Business Media. pp. 186–. ISBN 978-3-642-65192-2.
  2. ^ Hill RA, Makin HL, Kirk DN, Murphy GM (23 May 1991). Dictionary of Steroids. CRC Press. pp. 656–. ISBN 978-0-412-27060-4.
  3. ^ Burger A, Wolff ME (1996). Burger's Medicinal Chemistry and Drug Discovery: Therapeutic agents. Wiley. ISBN 978-0-471-57557-3.
  4. ^ a b Waldmann C, Soni N, Rhodes A (27 November 2008). "Diurectics and the Critical Ill". Oxford Desk Reference: Critical Care. OUP Oxford. pp. 187–. ISBN 978-0-19-922958-1.
  5. ^ Santambrogio R, Barabino M, Opocher E (21 June 2017). "Non-resection: Radiofrequency Ablation, Cryo, Microwave". In Bonjer HJ (ed.). Surgical Principles of Minimally Invasive Procedures: Manual of the European Association of Endoscopic Surgery (EAES). Springer. pp. 136–. ISBN 978-3-319-43196-3.
  6. ^ Kolkhof P, Bärfacker L (July 2017). "30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development". The Journal of Endocrinology. 234 (1): T125–T140. doi:10.1530/JOE-16-0600. PMC 5488394. PMID 28634268.